• Title/Summary/Keyword: Antihypertensive treatment

Search Result 139, Processing Time 0.028 seconds

Pharmacological Studies on the Antihypertensive Effects of Cinnarizine Coadministered with Propranolol or Metoprolol(III) -Effects on Biochemical Changes- (Cinnarizine을 Propranolol이나 Metoprolol과 병용할 때의 혈압강하효과(血壓降下效果)에 관한 약리학적(藥理學的) 연구(硏究)(III) -생화학적(生化學的) 변화(變化)에 대한 영향-)

  • Huh, In-Hoi;Ann, Hyung-Soo
    • YAKHAK HOEJI
    • /
    • v.28 no.5
    • /
    • pp.265-273
    • /
    • 1984
  • The effects of cinnarizine, $Ca^{2+}-antagonist$, on the antihypertensive effect of coadministered ${\beta}-blockers$, propranolol and metoprolol, were investigated in SHR. Drugs were coadministered orally for 4 weeks. Hemodynamic and biochemical changes induced by above drugs were determined to elucidate their mechanism of action. a) Cardiohypertropy of SHR was significantly improved by the treatment of ${\beta}-blockers$ as well as combination with cinnarizine and ${\beta}-blockers$. b) $Mg^{2+}-contents$ were increased in ventricle and decreased in plasma and aorta in all of the groups, especially in the group of propranolol with cinnarizine. c) c-GMP contents in ventricle were increased when cinnarizine was coadministered with propranolol, and c-GMP contents in aorta were increased when cinnarizine was coadministered with metoprolol, camparing with propranolol or metoprolol alone-treated group. d) Plasma renin activity appeared to be increased in cinnarizine treated alone, but reduced by combination with ${\beta}-blockers$. e) Triglycerides and $Na^+$ contents in serum were decreased in the group of metoprolol with cinnarizine, comparing with metoprolol alone-treated group. Increased $K^+\;and\;Ca^{2+}$excretions in urine by ${\beta}-blockers$ were inhibited by cinnarizine, so $Na^+/K^+$ excretion ratios were increased. Diuretic effects was showed in metoprolol alone treated group, but reduced when coadministered with cinnarizine.

  • PDF

Effects of Piroxicam on Pharmacodynamics and Pharmacokinetics of Nifedipine in Spontaneously Hypertensive Rats (피록시캄이 니페디핀의 약력학 및 약동학에 미치는 영향)

  • 최기환;박인숙;김동섭;정혜주
    • YAKHAK HOEJI
    • /
    • v.44 no.3
    • /
    • pp.245-250
    • /
    • 2000
  • Because nonsteroidal anti-inflammatory drugs are reported to cause fluid retention and hypertension by inhibition of prostaglandin synthesis, the effects of piroxicam on pharmacodynamics and pharmacokinetics of nifedipine were studied in male spontaneously hypertensive rats. They received nifedipine (0.5 mg/kg) alone or combined with piroxicam (5 mg/kg) intravenously. Plasma levels norepinephrine, an index of sympathetic stimulation, were measured prior to each treatment and 5 min after drug administration. Changes in blood pressure were examined serially and blood samples for analysis of nifedipine were also taken for 6 hr following drug administration. Plasma nifedipine concentration were assayed by HPLC and pharmacokinetic parameters were calculated. Blood pressure was reduced (p<0.01), but plasma norepinephrine level was increased (p<0.05) by nifedipine administration. Anti-hypertensive effect of nifedipine was potentiated (p<0.05) by piroxicam coadministration, but effect of nifedipine on plasma norepinephrine level was not affected. In case of rats received nifedipine and piroxicam, plasma nifedipine concentrations were higher (p<0.05) than those from rats received nifedipine alone at 2,3,4,5 and 6 hours following drug administration. The area under the plasma concentration vs. time curve was increased (p<0.05), while the elimination rate constant was decreased (p<0.01) by piroxicam coadministration. No significant differences were observed in the plasma clearance, apparent volume of distribution and elimination half-life. Thus, piroxicam not only potentiated antihypertensive effect of nifedipine, but also altered nifedipine pharmacokinetics in the rats. It is concluded that the potentiation of nifedipine antihypertensive effect might correlate with the increment of its plasma concentration by piroxicam coadministration.

  • PDF

THE THERAPEUTIC USES AND PHARMACOPEAL ACTION OF JIRJEER (Eruca sativa): A Review

  • Qaiyyum, Ifra Abdul;Nergis, Afiya
    • CELLMED
    • /
    • v.12 no.2
    • /
    • pp.7.1-7.8
    • /
    • 2022
  • The Unani System of Medicine (USM) is one of the traditional systems of medicine that deals with plants. Plants are large source of medicine. JIRJEER (Eruca sativa) is one of the plant origin drugs, has been used for various therapeutic purposes in USM. It contains Erucic acid (major contain), oleic acid, linoleic acid, saturated Fatty acids, Flavonoids, Phenolics, Glucosinolate, Vitamin C and Carotenoids. These active constituents are responsible for their actions described in Unani classical literature such as Muqqawwi-e-bah (Aphrodisiac), Muwallid-e-mani (Spermatomatogenic), Daf-e-sumoom (Antidote), Kasir-e-riyah (Carminative), Jaali (Cleanser/Detergent), Mudirr-e-bawl (Diuretic) wo Mudirr-e-hayd (Emmenogoggue), Muhammir (Rubefacient), Hazim (Digestive), Mulaiyan (Laxative), Muzliq-e-mani (Lubricant), Muddir-e-shir (Galactopoietic), Mufattih-e-Sudad (Deobstruent), Musakhin (Analgesic), Mulattif (Demulcent), Mufattit-i-hasah (Lithotriptic) and whole plant is considered as aphrodisiac. This is a review paper which discusses morphology, pharmacological action, ethno-medicinal and therapeutic uses of this medicinal plant in perspective of Unani medicine. This review has been done through online searches of databases such as PubMed, Google Scholar, Embase, science direct and hand search for classical textbook available in different libraries. It concluded that JIRJEER (Eruca sativa) is one of the best herbal medicines in treatment of Antiulcer, Antibacterial, Fertility, Hepato-protective, Hyperlipidemic, Antioxidant, Antihypertensive, Anti-inflammatory and Anti-edema, Nephro-protective, Antidiabetic, Antifungal and Anticancer properties.

Renal Effects of a Low Protein Diet and Antihypertensive Drugs on the Progression of Early Chronic Renal Failure in 5/6 Nephrectomized Rats (저단백 식이 및 항고혈압제의 투여가 만성신부전증의 진행에 미치는 영향에 관한 실험적 연구)

  • Kim, Kyo-Sun;Kim, Kee-Hyuk;Kim, Sang-Yun;Kang, Yong-Joo;Maeng, Won-Jae
    • Childhood Kidney Diseases
    • /
    • v.2 no.2
    • /
    • pp.125-132
    • /
    • 1998
  • Purpose : To study whether a low protein diet increase the efficacy of antihypertensive therapy on the progression of renal failure, we conducted an experimental study using 5/6 nephrectomized rats(n=63). Methods : At 7 days after surgery, rats were randomly assigned to three groups according to receiving antihypertensive drug: no antihypertensive drug (U), enalapril (E), and nicardipine (N), respectively and fed a low protein diet (6$\%$ protein). Proteinuria, mesangial matrix expansion score and glomerular volume were assessed at 4, 12 and 16 weeks after renal ablation. Results : Group U rats on a low protein diet developed progressive hypertension ($140{\pm}8,\;162{\pm}5,\;171{\pm}5\;and\;184{\pm}11\;mmHg$ at 4, 8, 12 and 16 weeks) which were controlled by E and N. Group U rats on a low protein diet developed proteinuria ($74{\pm}15\;mg/day$ at 16 weeks) which were decreased by E ($42{\pm}12 mg/day$) or N ($48{\pm}8 mg/day$) (p<0.05). Mesangial matrix expansion score and glomerular volume were not different between groups U, E and N on a low protein diet regardless of the antihypertensive drugs administered. Conclusion : A low protein diet did not affect blood pressure. Enalapril and nicardipine-treated rats on a low protein diet did not have different mesangial matrix expansion and glomerular volumes from rats on a low protein diet at 12 weeks and 16 weeks, in spite of the better controlling of systemic hypertension and lessening of proteinuria. Thus, combined treatment with a low protein diet and antihypertensive drugs didn't appear to show any addition,11 effects to attenuate glomerular injury.

  • PDF

Association Between Angiotensin II Receptor Blockers and the Risk of Lung Cancer Among Patients With Hypertension From the Korean National Health Insurance Service-National Health Screening Cohort

  • Moon, Sungji;Lee, Hae-Young;Jang, Jieun;Park, Sue K.
    • Journal of Preventive Medicine and Public Health
    • /
    • v.53 no.6
    • /
    • pp.476-486
    • /
    • 2020
  • Objectives: The objective of this study was to estimate the risk of lung cancer in relation to angiotensin II receptor blocker (ARB) use among patients with hypertension from the Korean National Health Insurance Service-National Health Screening Cohort. Methods: We conducted a retrospective cohort study of patients with hypertension who started to take antihypertensive medications and had a treatment period of at least 6 months. We calculated the weighted hazard ratios (HRs) and their 95% confidence intervals (CIs) of lung cancer associated with ARB use compared with calcium channel blocker (CCB) use using inverse probability treatment weighting. Results: Among a total of 60 469 subjects with a median follow-up time of 7.8 years, 476 cases of lung cancer were identified. ARB use had a protective effect on lung cancer compared with CCB use (HR, 0.75; 95% CI, 0.59 to 0.96). Consistent findings were found in analyses considering patients who changed or discontinued their medication (HR, 0.50; 95% CI, 0.32 to 0.77), as well as for women (HR, 0.56; 95% CI, 0.34 to 0.93), patients without chronic obstructive pulmonary disease (HR, 0.75; 95% CI, 0.56 to 1.00), never-smokers (HR, 0.64; 95% CI, 0.42 to 0.99), and non-drinkers (HR, 0.69; 95% CI, 0.49 to 0.97). In analyses with different comparison antihypertensive medications, the overall protective effects of ARBs on lung cancer risk remained consistent. Conclusions: The results of the present study suggest that ARBs could decrease the risk of lung cancer. More evidence is needed to establish the causal effect of ARBs on the incidence of lung cancer.

In-silico Studies of Boerhavia diffusa (Purnarnava) Phytoconstituents as ACE II Inhibitor: Strategies to Combat COVID-19 and Associated Diseases

  • Rahul Maurya;Thirupataiah Boini;Lakshminarayana Misro;Thulasi Radhakrishnan
    • Natural Product Sciences
    • /
    • v.29 no.2
    • /
    • pp.104-112
    • /
    • 2023
  • COVID-19 caused a catastrophe in human health. People infected with COVID-19 also suffer from various clinical illnesses during and after the infection. The Boerhavia diffusa plant is well known for its antihypertensive activity. ACE-II inhibitors and calcium channel blockers are reported as mechanisms for the antihypertensive activity of B. diffusa phytoconstituents. Various studies have said ACE-II is the virus's binding site to attack host cells. COVID-19 treatment commonly employs a variety of synthetic antiviral and steroidal drugs. As a result, other clinical illnesses, such as hypertension and hyperglycemia, emerge as serious complications. Safe and effective drug delivery is a prime objective of the drug development process. COVID-19 is treated with various herbal treatments; however, they are not widely used due to their low potency. Many herbal plants and formulations are used to treat COVID-19 infection, in which B. diffusa is the most widely used plant. The current study relies on discovering active phytoconstituents with ACE-II inhibitory activity in the B. diffusa plant. As a result, it can be used as a treatment option for patients with COVID-19 and related diseases. Different phytoconstituents of the B. diffusa plant were selected from the reported literature. The activity of phytoconstituents against ACE-II proteins has been studied. Molecular docking and ligand-protein interaction computation tools are used in the in-silico experiment. Physicochemical, drug-likeness, water solubility, lipophilicity, and pharmacokinetic parameters are used to evaluate phytoconstituents. Liriodenine has the best drug-likeness, bioactivity, and binding score characteristics among the selected ligands. The in-silico study aims to find the therapeutic potential of B. diffusa phytoconstituents against ACE-II. Targeting ACE-II also shows an effect against SARS-CoV-2. It can serve as a rationale for designing a drug for patient infected with COVID-19 and associated diseases.

Perioperative Hypertension Management during Facelift under Local Anesthesia with Intravenous Hypnotics

  • Chung, Ki Ho;Cho, Myeong Soo;Jin, Hoon
    • Archives of Plastic Surgery
    • /
    • v.44 no.4
    • /
    • pp.276-282
    • /
    • 2017
  • Perioperative hypertension is a phenomenon in which a surgical patient's blood pressure temporarily increases throughout the preoperative and postoperative periods and remains high until the patient's condition stabilizes. This phenomenon requires immediate treatment not only because it is observed in a majority of patients who are not diagnosed with high blood pressure, but also because occurs in patients with underlying essential hypertension who show a sharp increase in their blood pressure. The most common complication following facelift surgery is hematoma, and the most critical risk factor that causes hematoma is elevated systolic blood pressure. In general, a systolic blood pressure goal of <150 mm Hg and a diastolic blood pressure goal of >65 mm Hg are recommended. This article discusses the causes of increased blood pressure and the treatment methods for perioperative hypertension during the preoperative, intraoperative, and postoperative periods, in order to find ways to maintain normal blood pressure in patients during surgery. Further, in this paper, we review the causes of perioperative hypertension, such as anxiety, epinephrine, pain, and postoperative nausea and vomiting. The treatment methods for perioperative hypertension are analyzed according to the following 3 operative periods, with a review of the characteristics and interactions of each drug: preoperative antihypertensive medicine (atenolol, clonidine, and nifedipine), intraoperative intravenous (IV) hypnotics (propofol, midazolam, ketamine, and dexmedetomidine), and postoperative antiemetic medicine (metoclopramide and ondansetron). This article focuses on the knowledge necessary to safely apply local anesthesia with IV hypnotics during facelift surgery without the assistance of an anesthesiologist.

Effects of Captopril on the Active Angiotensin Converting Enzyme at the Pulmonary Endothelial Cells (Captopril에 의한 폐동맥 내피세포중 활성형 Angiotensin 전환효소의 변화)

  • 안형수
    • YAKHAK HOEJI
    • /
    • v.37 no.1
    • /
    • pp.41-48
    • /
    • 1993
  • The effect of captopril on the lung angiotensin converting enzyme (ACE) was investigated after 3 weeks oral administration (120~160 mg/kg/day) through drinking water in SpragueDawley rats. On the $^{125}$I-351A, an ACE inhibitor, binding assay in the isolated perpused lungs, the number of ACE molecules at the intrapulmonary endothelial cell surface was significantly decreased (p<0.001), and recovered to the normal level 7 days after discontinuation of captopril treatment. Intrapulmonary conversion ratio of Al to All was also significantly decreased (p<0.05) in the isolated perpused lungs. Bolus intravenous injection of angiotensin I did not showed pressor response in the both of systemic and pulmonary blood pressure of the anesthetized rats. ACE activity of the lung homogenates was also significantly reduced. These data consistently indicate the decrease of functionally active ACE molecule at the pulmonary artery after chronic captopril treatment. However, serum ACE activity was increased three fold in captopril treated rats compared to the normal rats. So, these results suggest that the functionally active ACE molecule at the pulmonary artery was still inhibited, which is directly associated with the antihypertensive effects, even if the total angiotensn converting enzyme induction was resulted after chronic captopril treatment.

  • PDF

The Antihypertensive Effect of Gyeok pal sang saeng yeok chim Acupuncture Treatment in Hypertension Patients (고혈압 환자에서 격팔상생역침범(隔八相生易鐵法)의 혈압강하 효과)

  • Han, Chang-Hyun;Han, Choong-Hee;Shin, Mi-Suk;Shin, Seon-Hwa;Choi, Sun-Mi
    • Journal of Acupuncture Research
    • /
    • v.23 no.4
    • /
    • pp.49-60
    • /
    • 2006
  • Objectives : The aim of the study was to investigate the antihypertensive effect of Gyeok pal sang saeng Yeok chim Acupuncture in hypertensive patients. Methods : We measured the blood pressure of the patients who were admitted in the Oriental Medical Clinic of Brother from 13th February 2006 to 13th May 2006. We included the patients only in case of the systolic blood pressure was over 120mmHg or diastolic blood pressure was over 80mmHg, thirty patients were treated by Gyeok pal sang saeng Yeok chim Acupuncture. In order to evaluate the effect of the Gyeok pal sang saeng Yeok chim Acupuncture, the blood pressure and pulse rate were measured before and after Acupuncture procedure total 10 times. Results : There were significant decrease in the systolic blood pressure and significant decrease in the diastolic blood pressure treated by Gyeok pal sang saeng Yeok chim Acupuncture 10 times but pulse rate was not significantly decreased. The effect of Gyeok pal sang saeng Yeok chim Acupuncture by measurement time on blood pressure were follows: In a systolic blood pressure and diastolic blood pressure was gradually deceased significantly from 1st to 10th but pulse rate was not significantly decreased. Conclusion : These results suggest that Gyeok pal sang saeng Yeok chim Acupuncture is effective in decreasing the systolic and diastolic blood pressure.

  • PDF

Effects of Antihypertensive Diets Mainly Consisting of Buckwheat, Potato, and Perilla Seed on Blood Pressures and Plasma Lipids in Normotensive and Spontaneously Hypertensive Rats (메밀, 감자, 들깨를 이용한 항고혈압 기능성 식이가 정상혈압쥐 및 본태성고혈압쥐에서 혈압 및 혈장지질에 미치는 영향)

  • 한찬규
    • Journal of Nutrition and Health
    • /
    • v.29 no.10
    • /
    • pp.1087-1095
    • /
    • 1996
  • The study was carried out to investigate a new type of functional foods with hypotensive effect which is critical in the prevention and treatment of hypertension and related circulatory diseases. The experimental diets(A, B, C) were prepared from plant based ingredients such as buckwheat, potato, perilla seed with different ratios formulated as an edible form appropriate for human consumption according to AIN-77 standard. Control group(D) was fed commercial rat chow. Twety-four 15-week-old SDR(Sprague Dawley rats) and twenty-four 20-week-old SHR(spontaneously hypertensive rats), weighing 200g respectively, were assigned to 4 treatments of 6 rats each in a completely randomized design. Blood pressure was measured at 7 day interval by tail-cuff sphygmomanometer using an IITC cuff pump and amplifier. The growth rates of both SHR and SDR were not statistically different in comparions with the control except those of diet B and C in SDR and SHR, respectively(p<0.05). When exprimental diets were fed, systolic blood pressure of SDR and SHR at day 28 had been lowered by 17-20 mmHg(ave. of 19.6mmHg for both strains) compared with the reference pressure at day 0. The levels of HDL-cholesterol were increased, while the levels of LDL-cholesterol consistently decreased in both strains when experimental diets were fed(p<.05). Plasma total cholesterol levels were not different among treatments. Plasma triglyceride levels were higher in control diet(commercial rat chow) due to two times higher fat content of control diet itself(p<.05). Atherogenic indices were lower compared to those of control when the experimental diets were fed in both strains (p,.05). The results suggest that the antihypertensive diets mainly consisting of plant-based ingredients may possibly effective in relieving hypertension as well as circulatory diseases.

  • PDF